Breaking News Instant updates and real-time market news.

MRNS

Marinus Pharmaceuticals

$4.09

-0.23 (-5.32%)

, SAGE

Sage Therapeutics

$166.38

-5.84 (-3.39%)

05:56
03/20/18
03/20
05:56
03/20/18
05:56

Mizuho sees Marinus following in footsteps of Sage, starts with Buy rating

Mizuho analyst Difei Yang last night initiated Marinus Pharmaceuticals with a Buy rating and $13 price target. The company, following in the footsteps of Sage Therapeutics (SAGE), is developing a similar molecule in Ganaxolone with potential in multiple central nervous system indications including postpartum depression, Yang tells investors in a research note. The analyst sees the recent positive data from Sage in postpartum depression and major depressive disorder as positive read-throughs for Marinus.

MRNS

Marinus Pharmaceuticals

$4.09

-0.23 (-5.32%)

SAGE

Sage Therapeutics

$166.38

-5.84 (-3.39%)

  • 30

    May

MRNS Marinus Pharmaceuticals
$4.09

-0.23 (-5.32%)

09/12/17
JMPS
09/12/17
NO CHANGE
Target $11
JMPS
Outperform
Marinus price target raised to $11 from $5 at JMP Securities
JMP Securities analyst Jason Butler raised his price target on Marinus Pharmaceuticals to $11 from $5 after the company reported Phase 2 clinical trial results in patients with CDKL5 disorder that he said support the potential for the drug to have "meaningful clinical benefit." The analyst, who added that the safety profile of ganaxolone "looks clean," keeps an Outperform rating on Marinus shares.
03/19/18
MZHO
03/19/18
INITIATION
Target $13
MZHO
Buy
Marinus Pharmaceuticals initiated with a Buy at Mizuho
Mizuho initiated Marinus Pharmaceuticals with a Buy and $13 price target.
SAGE Sage Therapeutics
$166.38

-5.84 (-3.39%)

01/31/18
BMOC
01/31/18
NO CHANGE
Target $203
BMOC
Outperform
Sage data support exploring sleep disorders, says BMO Capital
In a relatively small proof-of-concept study, SAGE-217 demonstrated a potential benefit in improving sleep, BMO Capital analyst Gary Nachman tells investors in a research note. These data support Sage Therapeutics exploring SAGE-217 for sleep disorders, the analyst adds. He believes validation for sleep disorders opens up the product to a "whole other large therapeutic area that could drive further upside." Nachman reiterates an Outperform rating on Sage with a $203 price target. The stock in morning trading is up 2.5% to $189.21.
02/26/18
MSCO
02/26/18
INITIATION
Target $225
MSCO
Overweight
Sage Therapeutics initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Matthew Harrison started Sage Therapeutics with an Overweight rating and $225 price target, stating that he sees brexanolone for post-partum depression providing a "solid base" that can generate $775M in peak U.S. sales. The real long-term value he sees, though, is from next-gen agent SAGE-217, which Harrison said has initial "robust" data in depression and expansion opportunities into bipolar disorder and insomnia.
02/26/18
02/26/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Walmart (WMT) initiated with a Neutral and Target (TGT) initiated with an Outperform at Credit Suisse. 2. Hudson (HUD) initiated with a Buy at Goldman Sachs, a Buy at UBS, an Equal Weight at Morgan Stanley and an Outperform at Credit Suisse. 3. VICI Properties (VICI) initiated with a Buy at Stifel, a Neutral at Goldman Sachs and an Equal Weight at Barclays. 4. Sage Therapeutics (SAGE) initiated with an Overweight at Morgan Stanley. 5. Sol-Gel Technologies (SLGL) initiated with a Buy at Jefferies and an Outperform at BMO Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/28/18
RHCO
02/28/18
NO CHANGE
Target $203
RHCO
Buy
Sage Therapeutics price target raised to $203 from $178 at SunTrust
SunTrust analyst Edward Nash raised his price target on Sage Therapeutics to $203, updating his model on the outline for Brexanolone's NDA filing for postpartum depression remaining on track for the first half of this year leading to a potential commercial launch. Nash keeps his Buy rating on Sage Therapeutics, adding that 2018 may be another catalyst-rich year with multiple trial initiations and readouts expected - including top-line data from the expanded Phase II study of SAGE-217 in PPD.

TODAY'S FREE FLY STORIES

NTRA

Natera

$18.99

0.84 (4.63%)

16:42
04/23/19
04/23
16:42
04/23/19
16:42
Hot Stocks
Integrated Core Strategies reports 5.3% passive stake in Natera »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

  • 28

    May

CRI

Carter's

$105.13

2.02 (1.96%)

16:42
04/23/19
04/23
16:42
04/23/19
16:42
Initiation
Carter's initiated  »

Carter's initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 16

    May

PLCE

Children's Place

$109.92

2.95 (2.76%)

16:41
04/23/19
04/23
16:41
04/23/19
16:41
Initiation
Children's Place initiated  »

Children's Place…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TAC

TransAlta

$6.88

-0.175 (-2.48%)

16:40
04/23/19
04/23
16:40
04/23/19
16:40
Hot Stocks
Mangrove Partners commences action in Ontario court against TransAlta »

Mangrove Partners, one of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    May

CP

Canadian Pacific

$219.33

0.215 (0.10%)

16:39
04/23/19
04/23
16:39
04/23/19
16:39
Hot Stocks
Breaking Hot Stocks news story on Canadian Pacific »

Canadian Pacific drops 5%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 05

    Jun

  • 13

    Nov

LLY

Eli Lilly

$117.51

2.07 (1.79%)

16:39
04/23/19
04/23
16:39
04/23/19
16:39
Upgrade
Eli Lilly rating change  »

Eli Lilly upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 30

    Apr

  • 04

    May

  • 06

    May

  • 07

    May

  • 08

    May

  • 09

    May

  • 18

    May

16:38
04/23/19
04/23
16:38
04/23/19
16:38
General news
API crude inventories for week of April 19 »

API reports that crude…

MTH

Meritage Homes

$49.75

1.275 (2.63%)

16:38
04/23/19
04/23
16:38
04/23/19
16:38
Earnings
Meritage Homes sees FY19 EPS $4.65-$4.95, consensus $4.69 »

CEO Steven Hilton said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 17

    May

HZN

Horizon Global

$2.77

0.04 (1.47%)

16:36
04/23/19
04/23
16:36
04/23/19
16:36
Hot Stocks
Horizon Global board approves amendment to declassify board structure »

Horizon Global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BURL

Burlington Stores

$161.96

1.76 (1.10%)

16:36
04/23/19
04/23
16:36
04/23/19
16:36
Earnings
Burlington Stores narrows Q1 EPS view to $1.21-$1.25 from $1.21-$1.31 »

Q1 consensus $1.29.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

TRMK

Trustmark

$34.47

0.7 (2.07%)

16:36
04/23/19
04/23
16:36
04/23/19
16:36
Earnings
Trustmark reports Q1 EPS 51c, consensus 52c »

Reports Q1 net interest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

PRK

Park National

$95.63

2.2 (2.35%)

16:36
04/23/19
04/23
16:36
04/23/19
16:36
Hot Stocks
Park National elects CEO Trautman as chairman and EVP Miller as president »

The board of directors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

MTH

Meritage Homes

$49.75

1.275 (2.63%)

16:35
04/23/19
04/23
16:35
04/23/19
16:35
Earnings
Meritage Homes reports Q1 EPS 65c, consensus 64c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 17

    May

LRN

K12

$36.23

0.805 (2.27%)

16:35
04/23/19
04/23
16:35
04/23/19
16:35
Earnings
K12 sees FY19 revenue $1.005B-$1.01B, consensus $1.01B »

Sees FY19 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

LRN

K12

$36.23

0.805 (2.27%)

16:34
04/23/19
04/23
16:34
04/23/19
16:34
Earnings
K12 reports Q3 EPS 44c, consensus 37c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

ROST

Ross Stores

$97.85

0.06 (0.06%)

, BURL

Burlington Stores

$161.96

1.76 (1.10%)

16:34
04/23/19
04/23
16:34
04/23/19
16:34
Hot Stocks
Burlington Stores CEO Thomas Kingsbury to step down, Michael O'Sullivan succeeds »

Burlington Stores (BURL)…

ROST

Ross Stores

$97.85

0.06 (0.06%)

BURL

Burlington Stores

$161.96

1.76 (1.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 22

    May

NAVI

Navient

$12.45

0.38 (3.15%)

16:33
04/23/19
04/23
16:33
04/23/19
16:33
Earnings
Navient reports Q1 adjusted EPS 58c, consensus 44c »

Reports Q1 revenue $257M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 02

    May

KALU

Kaiser Aluminum

$107.59

2 (1.89%)

, BA

Boeing

$374.04

-0.98 (-0.26%)

16:33
04/23/19
04/23
16:33
04/23/19
16:33
Hot Stocks
Kaiser Aluminum says Boeing 737 build rate reduction introduces uncertainty »

"The recent…

KALU

Kaiser Aluminum

$107.59

2 (1.89%)

BA

Boeing

$374.04

-0.98 (-0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 24

    Apr

  • 29

    Apr

  • 29

    May

  • 05

    Jun

DORM

Dorman Products

$93.44

0.53 (0.57%)

16:31
04/23/19
04/23
16:31
04/23/19
16:31
Hot Stocks
Dorman Products announces Joseph Braun as SVP and General Counsel »

Dorman Products announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

KALU

Kaiser Aluminum

$107.59

2 (1.89%)

16:31
04/23/19
04/23
16:31
04/23/19
16:31
Earnings
Kaiser Aluminum reports Q1 adjusted EPS $1.85, consensus $1.79 »

Reports Q1 revenue $395M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

TD

Toronto-Dominion

$56.14

-0.435 (-0.77%)

16:30
04/23/19
04/23
16:30
04/23/19
16:30
Hot Stocks
TD Bank Group sees TD Ameritrade's Q2 earnings to translate into C$266M »

TD Bank Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    May

NBHC

National Bank

$35.13

0.83 (2.42%)

16:30
04/23/19
04/23
16:30
04/23/19
16:30
Earnings
National Bank reports Q1 EPS 60c, consensus 51c »

Fully taxable equivalent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 09

    May

16:30
04/23/19
04/23
16:30
04/23/19
16:30
Options
Preliminary option volume of 19.3M today »

Preliminary option volume…

RHI

Robert Half

$68.83

1.46 (2.17%)

16:29
04/23/19
04/23
16:29
04/23/19
16:29
Earnings
Robert Half sees Q2 EPS 95c-$1.01, consensus $1.01 »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 22

    May

FE

FirstEnergy

$40.73

0.14 (0.34%)

16:28
04/23/19
04/23
16:28
04/23/19
16:28
Earnings
Breaking Earnings news story on FirstEnergy »

FirstEnergy backs FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 21

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.